Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It also offers MAT2501, an orally administered formulation of amikacin to treat chronic and acute bacterial infections, as well as non-tuberculosis mycobacterium. The company has strategic collaborations with the National Institute of Allergy and Infectious Diseases for the development of oral formulations of Gilead's remdesivir; BioNTech SE to evaluate the combination of mRNA formats with the LNC platform; and Genentech Inc. to develop oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey. more
Time Frame | MTNB | Sector | S&P500 |
---|---|---|---|
1-Week Return | -2.48% | -3.35% | -2.97% |
1-Month Return | 0.28% | -3.49% | -0.66% |
3-Month Return | -84.97% | -12.6% | 2.71% |
6-Month Return | -92.74% | -6.91% | 7.21% |
1-Year Return | -95.11% | 1.19% | 23.04% |
3-Year Return | -98.92% | -0.21% | 28.43% |
5-Year Return | -99.35% | 33.09% | 82.88% |
10-Year Return | -97.54% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 90.00K | 158.33K | 33.33K | 3.19M | 1.10M | [{"date":"2019-12-31","value":2.82,"profit":true},{"date":"2020-12-31","value":4.97,"profit":true},{"date":"2021-12-31","value":1.05,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":34.38,"profit":true}] |
Cost of Revenue | 11.23M | 14.36M | 781.49K | 16.68M | 14.49M | [{"date":"2019-12-31","value":67.36,"profit":true},{"date":"2020-12-31","value":86.09,"profit":true},{"date":"2021-12-31","value":4.69,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":86.87,"profit":true}] |
Gross Profit | (11.14M) | (14.20M) | (748.16K) | (13.49M) | (13.39M) | [{"date":"2019-12-31","value":-1114454800,"profit":false},{"date":"2020-12-31","value":-1420058500,"profit":false},{"date":"2021-12-31","value":-74815800,"profit":false},{"date":"2022-12-31","value":-1349000000,"profit":false},{"date":"2023-12-31","value":-1339300000,"profit":false}] |
Gross Margin | (12382.83%) | (8968.81%) | (2244.50%) | (423.15%) | (1221.99%) | [{"date":"2019-12-31","value":-12382.83,"profit":false},{"date":"2020-12-31","value":-8968.81,"profit":false},{"date":"2021-12-31","value":-2244.5,"profit":false},{"date":"2022-12-31","value":-423.15,"profit":false},{"date":"2023-12-31","value":-1221.99,"profit":false}] |
Operating Expenses | 19.01M | 24.36M | 24.77M | 11.10M | 24.86M | [{"date":"2019-12-31","value":76.47,"profit":true},{"date":"2020-12-31","value":98,"profit":true},{"date":"2021-12-31","value":99.62,"profit":true},{"date":"2022-12-31","value":44.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (18.92M) | (24.21M) | (24.73M) | (24.59M) | (23.77M) | [{"date":"2019-12-31","value":-1892100000,"profit":false},{"date":"2020-12-31","value":-2420655200,"profit":false},{"date":"2021-12-31","value":-2473475500,"profit":false},{"date":"2022-12-31","value":-2459000000,"profit":false},{"date":"2023-12-31","value":-2376600000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (17.37M) | (22.45M) | (23.28M) | (21.00M) | (22.94M) | [{"date":"2019-12-31","value":-1737300000,"profit":false},{"date":"2020-12-31","value":-2244683800,"profit":false},{"date":"2021-12-31","value":-2328341500,"profit":false},{"date":"2022-12-31","value":-2099700000,"profit":false},{"date":"2023-12-31","value":-2294200000,"profit":false}] |
Income Taxes | (1.79M) | (1.85M) | (2.11M) | (7.98M) | 773.11K | [{"date":"2019-12-31","value":-231.25,"profit":false},{"date":"2020-12-31","value":-239.02,"profit":false},{"date":"2021-12-31","value":-272.92,"profit":false},{"date":"2022-12-31","value":-1032.46,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (17.37M) | (22.45M) | (23.28M) | (21.00M) | (21.26M) | [{"date":"2019-12-31","value":-1737265100,"profit":false},{"date":"2020-12-31","value":-2244683800,"profit":false},{"date":"2021-12-31","value":-2328341500,"profit":false},{"date":"2022-12-31","value":-2099700000,"profit":false},{"date":"2023-12-31","value":-2126200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (15.59M) | (20.60M) | (21.17M) | (13.02M) | (22.94M) | [{"date":"2019-12-31","value":-1558518400,"profit":false},{"date":"2020-12-31","value":-2059896200,"profit":false},{"date":"2021-12-31","value":-2117345400,"profit":false},{"date":"2022-12-31","value":-1301500000,"profit":false},{"date":"2023-12-31","value":-2294200000,"profit":false}] |
EPS (Diluted) | (0.14) | (0.12) | (0.11) | (0.11) | (0.11) | [{"date":"2019-12-31","value":-14,"profit":false},{"date":"2020-12-31","value":-12,"profit":false},{"date":"2021-12-31","value":-11,"profit":false},{"date":"2022-12-31","value":-11,"profit":false},{"date":"2023-12-31","value":-11,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
MTNB | |
---|---|
Cash Ratio | 5.08 |
Current Ratio | 5.53 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
MTNB | |
---|---|
ROA (LTM) | -50.87% |
ROE (LTM) | -97.59% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
MTNB | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.23 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.77 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
MTNB | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 46.50 |
P/B | 0.19 |
Price/FCF | NM |
EV/R | 37.20 |
EV/Ebitda | NM |
PEG | NM |
Matinas BioPharma Holdings Inc (MTNB) share price today is $0.5666
Yes, Indians can buy shares of Matinas BioPharma Holdings Inc (MTNB) on Vested. To buy Matinas BioPharma Holdings Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MTNB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Matinas BioPharma Holdings Inc (MTNB) via the Vested app. You can start investing in Matinas BioPharma Holdings Inc (MTNB) with a minimum investment of $1.
You can invest in shares of Matinas BioPharma Holdings Inc (MTNB) via Vested in three simple steps:
The 52-week high price of Matinas BioPharma Holdings Inc (MTNB) is $18.49. The 52-week low price of Matinas BioPharma Holdings Inc (MTNB) is $0.5.
The price-to-earnings (P/E) ratio of Matinas BioPharma Holdings Inc (MTNB) is
The price-to-book (P/B) ratio of Matinas BioPharma Holdings Inc (MTNB) is 0.19
The dividend yield of Matinas BioPharma Holdings Inc (MTNB) is 0.00%
The market capitalization of Matinas BioPharma Holdings Inc (MTNB) is $3.01M
The stock symbol (or ticker) of Matinas BioPharma Holdings Inc is MTNB